Treatment by HIFU of prostate cancer: Survey of literature and treatment indications;Traitement par HIFU du cancer de la prostate: Revue de la littérature et indications de traitement

Progres en Urologie

Volumn 13, Issue 6, 2003, Pages 1428-1456

  Rebillard, Xavier ^a   Davin, Jean Louis ^b   Soulie, Michel ^c  

^a Clinique Beausoleil   (France)

^b Clinique Rhone Durance   (France)

^c CHU RANGUEIL   (France)

Author keywords

Ablatherm; HIFU; High intensity focused ultrasound; Prostate cancer; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RECURRENCE; CANCER SURVIVAL; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LIFE EXPECTANCY; MORBIDITY; PROSTATE CARCINOMA; REVIEW; SEXUAL FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VALIDATION PROCESS; MALE; PROSTATE TUMOR; ULTRASOUND THERAPY;

HUMANS; MALE; PROSTATIC NEOPLASMS; ULTRASONIC THERAPY;

EID: 11344271586     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. AMLING C.L., LERNER S.E., MARTIN S.K., et al. : Desoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J. Urol., 1999; 161 : 857-862.
2. ASTRO : Consensus statement : guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 1035-1041.
3. BEARD C.J., LAMB C., BUSWELL L., SCHNEIDER L., PROPERT K.J., GLADSTONE D., D'AMICO A., KAPLAN I. : Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1998 ; 41 : 257-262.
4. BEERLAGE H.P., THUROFF S., DEBRUYNE F.M., CHAUSSY C., DE LA ROSETTE J.J. : Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology, 1999 ; 54: 273-277.
5. BEERLAGE H.P., THUROFF S., MADERSBACHER S., ZLOTTA A.R., AUS G., DE REIJKE T.M., DE LA ROSETTE J.J. : Current status of minimally invasive treatment options for localized prostate carcinoma. Eur. Urol., 2000 ; 37 : 2-13.
6. BEERLAGE H.P., VAN LEENDERS G.J., OOSTERHOF G.O., WITJES J.A., RUIJTER E.T., VAN DE KAA C.A., DEBRUYNE P.M., DE LA ROSETTE JJ. : High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy : results of a prospective study. Prostate, 1999 ; 39 : 41-46.
7. BENOIT R.M., NASLUND M.J., COHEN J.K. : Complications after prostate brachytherapy in the medicare population. Urology, 2000 ; 55 : 91-96.
8. BENOIT R.M., NASLUND M.J., COHEN J.K. : Complications after radical retropubic prostatectomy in the Medicare population. Urology, 2000 ; 56 : 116-120.
9. BEYER D.C., PRIESTLEY J.B. : Biochemical Disease-free Survival Following 125I Prostate Implantation. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37: 559-563.
10. BRACHMAN D.G., THOMAS T., HILBE J., BEYER D.C. : Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients : results from a single practice. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 111-117.
11. BRANDEIS J.M., LITWIN M.S., BURNISON C.M., REITER R.E. : Quality of life outcomes after brachytherapy for early stage prostate cancer. J. Urol., 2000 ; 163 : 851-857.
12. BROWN D., COLONIAS A., MILLER R., BENOIT R., COHEN J., AESHOUN Y., GALLOWAY M., KARLOVITS S., WU A., JOHNSON M., QUINN A., KALNICKI S. : Urinary Morbidity with a Modified Peripheral Loading Technique of Transperineal 1251 Prostate Implantation. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 4 : 353-360.
13. CATALONA W.J., CARVALHAL G.F., MAGER D.E., SMITH D.S. : Potency, continence and complications rates in 1870 consecutive radical retropubic prostatectomies. J. Urol., 1999 ; 162 : 433-438.
14. CHAPELON J.Y., MARGONARI J., THEILLÈRE Y., GORRY F., VERNIER F., BLANC E., GELET A. : Effects of High-Energy Focused Ultrasound on Kidney Tissue in the Rat and the Dog. Eur. Urol., 1992 ; 22 : 147-152.
15. CHAPELON J.Y., MARGONARI J., VERNIER F., GORRY P., ECOCHARD R., GELET A. : In vivo effects of High Intensity Ultrasound on Prostatic Adenocarcinoma Dunning R3327. Cancer Research, 1992 ; 52 : 6353-6357.
16. CHAUSSY C., THÜROFF S. : Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J. Endourol., 2001 ; 15 : 437-440 ; discussion 447-448.
17. CHAUSSY C., THÜROFF S. : The Status of High-intensity Focused Ultrasound in the Treatment of Localized Prostate Cancer and the Impact of a Combined Resection. Curr. Urol. Rep., 2003 ; 4 : 248-252.
18. CHAUSSY C., THÜROFF S. : High Intensity Focused Ultrasound in Prostate Cancer : Results after 3 Years. Mol. Urol., 2000 ; 4 : 179-182.
19. CHAUSSY C., THÜROFF S. : High-intensive focused ultrasound in localized prostate cancer. J. Endourol., 2000 ; 14 : 293-299.
20. CHAVRIER F., CHAPELON J.Y., GELET A., CATHIGNOL D. : Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation hubbies. J. Acoust. Soc. Am., 2000 ; 108 : 432-440.
21. CHEUNG R., ALTSCHULER M.D., D'AMICO A.V., MALKOWICZ S.B., WEIN A.J., WHITTINGTON R. : ROC optimization may improve risk stratification of prostate cancer patients. Urology, 2001 ; 57 : 286-290.
22. CRITZ F.A., WILLIAMS W.H., HOLLADAY C.T., LEVINSON A.K., BENTON J.B., HOLLADAY D.A., SCHNELL F.J. JR, MAXA L.S., SHRAKE P.D. : Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology, 1999 ; 54 : 968-971.
23. CRITZ F. et al. : A standard definition of disease freedom is needed for prostate cancer : undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J. Urol., 2002 ; 167 : 1310-1313.
24. D'ALCHE-GAUTIER M.J., BENSADOUN H., MARCHAND C. : Impact budgétaire d'une innovation à l'hôpital ; exemple du coût du traitement du cancer localisé de la prostate par Ultrasons Focalisés de Haute Intensité (UFHI). J. Econ. Med., 2003 ; 4 : 225-238.
25. D'AMICO A.V., WHITTINGTON R., MALKOWICZ S.B., SCHULTZ D., BLANK K., BRODERICK G.A., TOMASZEWSKI J.E., RENSHAW A.A., KAPLAN I., BEARD C.J., WEIN A. : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 1998 ; 280 : 969-974.
26. D'AMICO A.V., SCHULTZ D., SCHNEIDER L., HURWITZ M., KANTOFF P.W., RICHIE J.P. : Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J. Urol., 2000 ; 163 : 1797-1801.
27. D'AMICO A.V., COTE K., LOFFREDO M., et al. : Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J. Urol., 2003 ; 169: 1320-1324.
28. DESAI J., STOCK R.G., STONE N.N., IANNUZZI C., DE WYNGAERT J.K. : Acute Urinary Morbidity Following 1-125 Interstitial Implantation of the Prostate Gland. Radiat. Oncol. Investig., 1998 ; 3 : 135-141.
29. DOWNS T.M., SADETSKY N., PASTA D.J., GROSSFELD G.D., KANE C.J., MEHTA S.S., CARROLL P.R., LUBECK D.P. : Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer-data from capsure. J. Urol., 2003 ; 170 : 1822-1827.
30. FIVEASH J.B., HANKS G., ROACH M., WANG S., VIGNEAULT E., McLAUGHLIN P.W., SANDLER H.M. : 3D conformal radiation therapy (3DCRT) for high grade prostate cancer : a multi-institutional review. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 335-342.
31. GELBLUM D.Y., POTTERS L., ASHLEY R., WALDBAUM R., WANG X.H., LEIBEL S. : Urinary Morbidity Following Ultrasound-guided Transperineal Prostate Seed Implantation. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 45: 59-67.
32. GELBLUM D.Y., POTTERS L. : Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 119-124.
33. GELET A., CHAPELON J.Y., BOUVIER R., ROUVIERE O., LASNE Y., LYONNET D., DUBERNARD J.M. : Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J. Endourol, 2000 ; 14 : 519-28. Erratum in : J. Endourol., 2000 ; 14 : 697.
34. GELET A., CHAPELON J.Y., BOUVIER R., ROUVIERE O., LYONNET D., DUBERNARD J.M. : Transrectal high intensity focused ultrasound for the treatment of localized prostate cancel : factors influencing the outcome. Eur. Urol., 2001 ; 40 : 124-129.
35. GELET A., CHAPELON J.Y., MARGONARI J., THEILLERE Y., GORRY F., CATHIGNOL D., BLANC E. : Prostatic tissue destruction by high-intensity focused ultrasound : experimentation on canine prostate. J. Endourol., 1993 ; 7 : 249-253.
36. GELET A., CHAPELON J.Y., BOUVIER R., SOUCHON R., PANGAUD C., ABDELRAHIM A.F., CATHIGNOL D., DUBERNARD J.M. : Treatment of Prostate Cancer with Transrectal Focused Ultrasound : Early Clinical Experience. Eur. Urol., 1996 ; 29 : 174-183.
37. GELET A., CHAPELON J.Y., MARGONARI J., THEILLERE Y., GORRY F., SOUCHON R., BOUVIER R. : High Intensity Focused Ultrasound Experimentation on Human Benign Prostatic Hypertrophy. Eur. Urol., 1993; 23 : 44-47.
38. GIGNOUX B.M., SCOAZEC J.Y., CURIEL L., BEZIAT C., CHAPELON J.Y. : High intensity focused ultrasonic destruction of hepatic parenchyma. Ann. Chir., 2003 ; 128 : 18-25.
39. GRADO G.L., COLLINS J.M., KRIEGSHAUSER J.S., et al. : Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology, 1999 ; 53 : 2-10.
40. GUILLONNEAU B., EL-FETTOUH H., BAUMERT H., CATHELINEAU X., DOUBLET J.D., FROMONT G., VALLANCIEN G. : Laparoscopic radical prostatectomy : Oncological evaluation after 1,000 cases at Montsouris Institute. J. Urol., 2003 ; 169 : 1261-1266.
41. HOLLISTER T.C., ZELEFSKY M.J., WOLFE T., RABEN A., WALLNER K. : Late toxicity of transperineal permanent 125 iodine implantation of the prostate for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1998 ; 42 : 220.
42. HULL G.W., RABBANI F., ABBAS F., WHEELER T.M., KATTAN M.W., SCARDINO P.T. : Cancer control with radical prostatectomy alone in 1 000 consecutive patients. J. Urol., 2002 ; 167 : 528-534.
43. JONLER M., RITTER M.A., BRINKMANN R., MESSING E.M., RHODES P.R., BRUSKEWITZ R.C. : Sequelae of definitive therapy for prostate cancer localized to the pelvis. Urology, 1994 ; 44 : 876-882.
44. KATZ R., SALOMON L., HOZNEK A., DE LA TAILLE A., ANTIPHON P., ABBOU C.C. : Positive surgical margins in laparoscopic radical prostatectomy : The impact of apical dissection, bladder neck remodeling and nerve preservation. J. Urol., 2003 ; 169 : 2049-2052.
45. KESTIN L.L., VICINI F.A., ZIAJA E.L., STROMBERG J.S., FRAZIER R.C., MARTINEZ A.A. : Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer, 1999 ; 86 : 1557-1566.
46. LITWIN M.S., HAYS R.D., FINK A., GANZ P.A., LEAKE B., LEACH G.E., BROOK R.H. : Quality-of-life outcomes in men treated for localized prostate cancer. JAMA, 1995 ; 273 : 129-135.
47. LYONS J.A., KUPELIAN P.A., MOHAN D.S., REDDY C.A., KLEIN E.A.: Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology, 2000 ; 55 : 85-90.
48. MADALINSKA J.B., ESSINK-BOT M.L., DE KONING H.J., KIRKELS W.J., VAN DER MAAS P.J. : Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for sceen-detected or clinically diagnosed localized prostate cancer. J. Clin. Oncol., 2001 ; 19 : 1587-1588.
49. MADERSBACHER S., KRATZIK C., MARBERGER M. : Prostatic tissue ablation by transrectal high intensity focused ultrasound : histological impact and clinical application. Ultrason. Sonochem., 1997 ; 4 : 175-179.
50. MADERSBACHER S., PEDEVILLA M., VINGERS L., SUSANI M., MARBERGER M. : Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res., 1995 ; 55 : 3346-3351.
51. MERRICK G.S., BUTLERW.M., LIEF J.H. AND DORSEY A.T. :Temporal Resolution of Urinary Morbidity Following Prostate Brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 121-128.
52. MERRICK G.S., WALLNER K., BUTLER W.M., LIEF J.H., SUTLIEF S. : Short-term Sexual Function after Prostate Brachytherapy. Int. J. Cancer, 2001 ; 96 : 313-319.
53. MERRICK G.S., WALLNER K., BUTLER W.M., GALBREATH R.W., LIEF J.H., BENSON M.L. : A Comparison of Radiation Dose to the Bulb of the Penis in Men with and without Prostate Beachytherapy-Induced Erectile Dysfonction. Int. J. Radiat. Oncol. Biol. Phys., 2001 ; 50 : 597-604.
54. MERRICK G.S., BUTLER W.M., WALNER K.E., LIEF J.H., GALBREATH R.W. : Prophylactic versus Therapeutic Alpha-Blockers after Permanent Prostate Brachytherapy. Urology, 2002 ; 60 : 650-655.
55. MERRICK G.S., BUTLER W.M., TOLLENAAR E.G., GALBREATH R.W. AND LIEF J.H. : The Dosimetry of Prostate Brachytherapy-induced Urethral Strictures. Int. J. Radiat. Oncol. Biol. Phys., 2002 ; 52 : 461-468.
56. MERRICK G.S., BUTLER W.M., GALBREATH R.W., STIPETICH R.L., ABEL,L.J., LIEF J.H. : Erectile Function after Permanent Prostate Brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2002 ; 52 : 893-902.
57. OOSTERHOF G.O.N., CORNEL E.B., SMITS G.A.H.J., DEBRUYNE F.M.J., SCHALKEN J.A. : Influence of High Intensity Focused Ultrasound on the Development of Metastases. Eur. Urol., 1997 ; 32 : 91-95.
58. PEREZ C.A., LEE H.K., ANASATASIOS G., LOCKETT M.A. : Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 1994 ; 28 : 811-819.
59. PISTERS L.L., VON ESCHENBACH, SCOTT S.M., et al. : The efficacy and complications of salvage cryotherapy of the prostate. J. Urol., 1997 ; 157 : 921-925.
60. POISSONNIER L. : Place des ultrasons focalisés de haute intensité dans le traitement des cancers localisés de prostate (échecs de radiothérapie exclus) à propos de 145 patients Thèse de Doctorat en Médecine, Université Claude Bernard - Lyon 1, soutenue le 8 avril 2002.
61. POISSONNIER L., GELET A., CHAPELON J.Y., BOUVIER R., ROUVIERE O., PANGAUD C., LYONNET D., DUBERNARD J.M. : Résultats du traitement par ultrasons focalisés transrectaux du cancer localisé de la prostate (120 patients avec PSA ≤ à 10 ng/ml). Prog. Urol., 2003 ; 13 : 60-72.
62. POTTERS L., CHA C., OSHINSKY G., VENKATRAMAN E., ZELEFSKY M., LEIBEL S. : Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J. Sci. Am., 1999 ; 5 : 301-306.
63. POTTERS L., TORRE T., FEARNP.A., LEIBEL S.A., KATTAN M.W. : Potency after Permanent Prostate Brachytherapy for Localized prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys., 2001 ; 50 : 1235-1242.
64. POUND C.R., PARTIN A.W., EISENBERGER M.A., CHAN D.W., PEARSON J.D., WALSH P.C. : Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 1999 ; 281 : 1591-1597.
65. RADGE H., BLASKO J.C., GRIMM P.D., KENNY G.M., SYLVESTER J.E., HOAK D.C., LANDIN K., CAVANAGH W. : Interstitial Iodine-125 Radiation without Adjuvant Therapy in the Treatment of Clinically Localized Prostate Carcinoma. Cancer, 1997 ; 80 : 442-453.
66. RAGDE H., ELGAMAL A.A., SNOW P.B., BRANDT J., BARTOLUCCI A.A., NADIR B.S., KORB L.J. : Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer, 1998 ; 83 : 989-1001.
67. REBILLARD X., VILLERS A., RUFFION A., BEUZEBOC P., SOULIE M., RICHAUD P., BARRE C., ESCHWEGE P., FONTAINE E., MOLINIE V., MOREAU J.L., PENEAU M., RAVERY V., STAERMAN F. et le Comité de Cancérologie de l'AFU : Recommandations 2002 sur le cancer de prostate. Prog. Urol., 2002 ; 12 : 31-67.
68. REMONTET L., ESTEVE J., BOUVIER A.M., GROSCLAUDE P., LAUNOY G., MENEGOZ F., EXBRAYAT C., TRETARE B., CARLI P.M., GUIZARD A.V., TROUSSARD X., BERCELLI P., COLONNA M., HALNA J.M., HEDELIN G., MACE-LESEC'H J., PENG J., BUEMI A., VELTEN M., JOUGLA E., ARVEUX P., LE BODIC L., MICHEL E., SAUVAGE M., SCHVARTZ C., FAIVRE J. : Incidence et mortalité des cancers en France 1978-2000. Rev. Epidémiol. Santé Publique, 2003 ; 51 : 3-30.
69. ROBERTS W.W., BERGSTRALH E.J., BLUTE M.L., SLEZAK J.M., CARDUCCI M., HAN M., EPSTEIN J.I., EISENBERGER M.A., WALSH P.C., PARTIN A.W. : Contempory identification of patients at high risk of early prostate cancer recurrence after radical retrobupic prostatectomy. Urology, 2001 ; 57 : 1033-1037.
70. ROUVIERE O., LYONNET D., RAUDRANT A., COLIN-PANGAUD C., CHAPELON J.Y., BOUVIER R., DUBERNARD J.M., GELET A. : MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur. Urol., 2001 ; 40 : 265-274.
71. SEBAG M. : Traitement du cancer localisé de la prostate : comparaison de la prostatectomie radicale, de la radiothérapie conformationnelle et de la curiethérapie - Etude coût- efficacité et qualité de vie. Rapport de Thèse. Université Aix-Marseille II. Année Universitaire 1999-2000.
72. SEDELAAR J.P., AARNINK R.G., VAN LEENDERS G.J., BEERLAGE H.P., DEBRUYNE F.M., WIJKSTRA H., DE LA ROSETTE J.J. : The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer. Eur. Urol., 2000 ; 37 : 559-568.
73. SHARKEY J., CHOVNICK S.D., BEHAR R.J., PEREZ R., OTHEGUY J., SOLC Z., HUFF W., CANTOR A. : Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate : a preliminary report of 434 patients. Urology, 1998 ; 51 : 796-803.
74. STANFORD J.L., FENG Z., HAMILTON A.S., GILLILAND F.D., STEPHENSON R.A., ELEY J.W., ALBERTSEN P.C., HARLAN L.C., POTOSKY A.L. : Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. JAMA, 2000 ; 283 : 354-360.
75. STOCK R.G., STONE N.N., IANNUZZI C. : Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 267-272.
76. STOKES S.H., REAL J.D., ADAMS P.W., CLEMENTS J.C., WUERTZER S., KAN W. : Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 337-341.
77. STOKES S.H. : Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 129-136.
78. STOREY M.R., LANDGREN R.C., COTTONE J.L., STALLINGS J.W., LOGAN C.W., FRAISER L.P., ROSS C.S., KOCK R.J., BERKLEY L.W., HAUER-JENSEN M. : Transperineal 125 iodine implantation for treatment of clinically localized prostate cancer : 5-year tumor control and morbidity. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 43 : 565-570.
79. TALCOTT J.A., RIEKER P., PROPERT K.J., CLARK J., KAUTOFF P., BEARD C., KAPLAN I., LOUGHLIN K., RICHIE J., WISHNOW K. : Long-term complications of treatment for early prostate cancer : 2-year follow-up in a prospective multi-institutional outcomes study - Proceedings of the 32nd meeting of ASCO. J. Clin. Oncol., 1996 ; 15 : 252.
80. TALCOTT J.A., RIEKER P., CLARK J.A., PROPERT K.J., WEEKS J.C., BEARD C.J., WISHNOW K.I., KAPLAN I., LOUGHLIN K.R., RICHTE J.P., KANTOFF P. : Patient-reported symptoms after primary therapy for early prostate cancer : Results of a prospective cohort study. J. Clin. Oncol., 1998 : 16 ; 275-283.
81. TALCOTT J.A., CLARK J.C., STARK P. et al. : Long-term treatment-related complications of brachytherapy for early prostate cancer : A survey of treated patients. Proceedings of ASCO 1999 ; 18 : 311.
82. TERK M.D., STOCK R.G., STONE N.N. : Identification of Patients at Increased Risk for Prolonged Urinary Retention Following Radioactive Seed Implantation of the Prostate. J. Urol., 1998 ; 16 : 1379-1382.
83. THEODORESCU D., GILLENWATER J.Y., KOUTOUVELIS P.G. : Prostatourethral- rectal fistula after prostate brachytherapy. Cancer, 2000 ; 89 : 2085-2091.
84. THÜROFF S., CHAUSSY C. : High Intensity Focused Ultrasound : Complications and Adverse Events. Mol. Urol., 2000 ; 4 : 183-187 ; discussion 189.
85. THÜROFF S., CHAUSSY C., VALLANCIEN G., WIELAND W., KIELH.J., LE DUC A., DESGRANDCHAMPS F., DE LA ROSETTE J., GELET A. : High-Intensity Focused Ultrasound and localized prostate cancer : efficacy results from the European Multicentric Study. J. Endourol., 2003 ; 17 : 673-677.
86. UCHIDA T., SANGHVI N.T., GARDNER T.A., KOCH M.O., ISHII D., MINEI S., SATOH T., HYODO T., IRIE A., BABA S. : Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2N0M0 localized prostate cancer : a preliminary report. Urology, 2002 ; 59: 394-398 ; discussion 398-399.
87. VAN LEENDERS G.J., BEERLAGE H.P., RUIJTER E.T., DE LA ROSETTE J.J., VAN DE KAA C.A. : Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J. Clin. Pathol., 2000 ; 53 : 391-394.
88. VILLERS A., REBILLARD X., SOULIE M., DAVIN J.L., COLOBY P., MOREAU J.L., MEJEAN A., IRANI J., COULANGE C., MANGIN P. : Dépistage du cancer de la prostate. Prog. Urol., 2003 ; 13 : 209-214.
89. WALLNER K., ROY J., HARRISON L. : Dosimetry Guidelines to Minimize Urethral and Rectal Morbidity Following Transperineal I-125 Prostate Brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 1995 ; 32 : 465-471.
90. WALLNER K., LEE H., WASSERMAN S., DATTOLI M. : Low Risk of Urinary Incontinence Following Prostate Brachytherapy in Patients with a prior Transurethral Prostate Resection. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 565-569.
91. WALSH P.C., PARTIN A., EPSTEIN J.I. : Cancer control and quality of life following anatomical radical retropubic prostatectomy : results at 10 years. J. Urol., 1994; 152: 1831-1836.
92. ZELEFSKY M.J., WALLNER K.E., LING C.C., RABEN A., HOLLISTER T., WOLFE T., GRANN A., GAUDIN P., FUKS Z., LEIBEL S.A. : Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin. Oncol., 1999 ; 17 : 517-522.
93. ZELEFSKY M.J., COWEN D., FUKS Z., SHIKE M., BURMAN C., JACKSON A., VENKATRAMEN E.S., LEIBEL S.A. : Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer, 1999 ; 85 : 2460-2468.
94. ZELEFSKY M.J., HOLLISTER T., RABEN A., MATTHEWS S., WALLNER K.E. : Five-Year Biochemical Outcome and Toxicity with Transperineal CT-Planned I-125 Prostate Implantation for Patients with Localized Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 1261-1266.
95. ZINCKE H., OESTERLING J.E., BLUTE M.L., BERGSTRALH E.J., MYERS R.P., BARRETT D.M. : Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 1994; 152: 1850-1857.